13 August 2014Americas
Biotech industry reacts to USPTO’s Myriad/Mayo guidelines
A group of 12 international biotechnology associations has written to the US Patent and Trademark Office (USPTO), raising concerns about the office’s guidelines on determining the patent eligibility of natural products in the aftermath of the Myriad and Mayo cases.
